Domin ci gaba da inganta yaduwar ilimin kimiyya na rigakafin cutar kansar mahaifa ga mata masu shekarun da suka dace da kuma inganta lafiyar mata, shirin rigakafin cutar kansar mahaifa na farko yana nuna taken “Kyakkyawan lafiya, kyakkyawar ajin fada, jagorar rawar da kimiyya ke takawa. ” aka bude a birnin Beijing.Tan Xianjie, babban likitan likitan mata da mata na asibitin kwalejin likitanci na Beijing Union, da Zou Shien, babban likitan mata da mata masu juna biyu na asibitin mata da mata masu juna biyu na jami'ar Fudan, da Chen Qiuping, shugaban sashen kula da lafiya na cibiyar kula da lafiyar al'umma ta Liulitun. , gundumar Chaoyang da ke nan birnin Beijing, ta dauki matakin fadakar da jama'a game da cutar sankarar mahaifa da rigakafin cutar daji a cikin wani sabon salo da kalmomi na ban dariya, da taimakawa wajen hanzarta kawar da cutar kansar mahaifa.
Yawan kamuwa da cutar sankarar mahaifa yana ƙaruwa, yana nuna ƙarami
Ciwon daji na mahaifa cuta ce ta mace da ta zama ruwan dare gama gari.A cikin 2020, za a sami kusan sabbin cututtukan 604000 na cutar sankarar mahaifa da mutuwar 342000 a duk duniya.A shekarar 2020, an samu sabbin mutane 110000 da suka kamu da cutar sankarar mahaifa a kasar Sin, kuma adadin wadanda suka mutu ya kai kusan 59000, wanda ya kai kashi 18% na yawan wadanda suka kamu da cutar sankarar mahaifa a duniya da kuma kashi 17% na adadin wadanda suka mutu sakamakon cutar kansar mahaifa.Yayin da bunkasuwar tattalin arziki da zamantakewar jama'ar kasar Sin, da masana'antu, da biranen kasar Sin ke ci gaba da habaka, kuma yanayin rayuwa da rayuwar mazauna wurin ke canjawa cikin sauri, yawan kamuwa da cutar kansar mahaifa na ci gaba da karuwa, lamarin da ke nuna yanayin matasa, kuma matsakaicin shekaru na ci gaba da raguwa.
A cikin 2020, Hukumar Lafiya ta Duniya ta sanar da Dabarun Duniya don Sauƙaƙe Kawar da Ciwon Sankara na mahaifa.A cikin 'yan shekarun nan, kasar Sin ta ba da muhimmanci sosai ga lafiyar mata, tare da aiwatar da manufofi daban-daban na rigakafin cutar kansar mahaifa da muhimman ayyuka.A watan Janairun 2023, Hukumar Lafiya ta Kasa da sauran sassan 10 sun ba da sanarwar Buga da Rarraba Tsarin Ayyuka don Saukar da Ciwon Ciwon Sankara (2023-2030), wanda ya nuna karara cewa ya zuwa 2030, aikin gwaji na rigakafin HPV don Za a ci gaba da ciyar da 'yan matan da suka kai makaranta matsayi;Adadin gwajin cutar kansar mahaifa a cikin matan da suka kai makaranta ya kai kashi 70%;Adadin maganin kansar mahaifa da raunukan da suka rigaya ya kai kashi 90%.
Tan Xianjie ya yi nuni da cewa, ko da yake ciwon sankarar mahaifa yana da hadari, amma a zahiri akwai damammaki guda uku na rigakafinta, wato rigakafin matakai uku, wato rigakafin farko don rage kamuwa da cutar ta HPV ta hanyar allurar rigakafin cutar ta HPV da salon rayuwa mai kyau, rigakafin biyu zuwa kan lokaci. ganowa da magance cututtukan da suka rigaya ya faru ta hanyar gwajin cutar kansar mahaifa, da rigakafin manyan makarantu don yin tiyata da rediyo don tabbatar da kansar mahaifa.
Yi allurar da wuri-wuri, kar a manne wa rigakafin HPV mai tsada
Kasar Sin ita ce kasar da ta fi yawan adadin rigakafin cutar HPV da aka amince da ita a duniya.Akwai maganin rigakafi guda biyar na HPV ga mata masu shekaru 9 zuwa 45, gami da rigakafin cutar HPV da aka shigo da su, rigakafin HPV mai ƙarfi huɗu, rigakafin HPV mai ƙarfi tara da allurar rigakafin HPV na gida biyu.Alkaluma sun nuna cewa, daga shekarar 2018 zuwa 2020, yawan allurar rigakafin cutar HPV a kasar Sin ya karu a kowace shekara, daga allurai miliyan 3.417 a shekarar 2018 zuwa miliyan 12.279 a shekarar 2020, amma har yanzu ana bukatar a inganta yawan rigakafin.
Zou Shien ya ce wasu abokai mata sun dage da jiran rigakafin HPV mai tsada maimakon allurar rigakafi, don haka sun rasa “lokacin zinare” don rigakafin cutar kansar mahaifa.Ya kamata mu guje wa jiran jiran rigakafin HPV masu tsada, wanda ba zai cancanci asara ba idan kamuwa da cuta yayin jira.Ya kamata mu ƙarfafa jama'a su bi ka'idar "alurar riga kafi da wuri", kuma su zaɓi sassauƙa bisa albarkatun rigakafin da yanayin tattalin arzikinsu.
A kasar Sin, fiye da kashi 84.5% na cututtukan sankarar mahaifa suna da alaƙa da kamuwa da cutar HPV nau'in 16 da 18.Dangane da haka, Zou Shien ya nuna cewa HPV16 da HPV18 sune nau'ikan nau'ikan nau'ikan haɗarin HPV mafi mahimmanci, kuma ana iya rufe alluran rigakafin HPV na bivalent, huɗu-valent da tara.Alurar riga kafi na bivalent na HPV na iya hana yawancin kansar mahaifa da raunukan da ba a taɓa gani ba, kuma rigakafin kansa ya “isa”.Komai farashin maganin alurar riga kafi, rigakafin farko yana da “daraja”.
Haɓaka allurar rigakafi a lokacin ƙuruciyar kuma inganta rigakafin farko da layin kariya na kansar mahaifa
A matsayinsa na “mai tsaron ƙofa” na lafiyar mazauna, cibiyar sabis na kiwon lafiyar al’umma ta tushen ciyawa tana taka muhimmiyar rawa wajen rigakafin cutar kansar mahaifa a matakin ciyawa.Ta hanyar aiwatar da ayyuka kamar yaɗa ilimin kimiyyar cutar kansar mahaifa da rigakafin rigakafin HPV, yana yada bayanan kimiyya, daidai kuma ingantaccen ilimin kimiyyar cutar kansar mahaifa kuma yana haɓaka ƙimar allurar rigakafin cutar ta HPV.A sa'i daya kuma, samar da allurar rigakafin cutar ta HPV ga matan da suka kai makaranta shi ma yana daya daga cikin muhimman ayyuka na sashen kula da lafiya na cibiyar kula da lafiya ta al'umma.
Chen Qiuping ya yi nuni da cewa, a halin yanzu, cibiyoyin kula da lafiya na al'umma na iya yin allurar rigakafin cutar ta HPV da ake shigowa da su daga waje da na cikin gida;A daidai lokacin da mashahuran cututtukan kimiyya, tare da taimakon dandalin ajiyar kan layi, ƙarin mutanen da ke buƙatar allurar rigakafin HPV za a samar da tashar ajiyar wuri mai sauri.Taimaka wajen hanzarta kawar da kansar mahaifa ta hanyar ci gaba da inganta ayyukan rigakafin HPV."Har ila yau, muna tunatar da mata game da shekarun da suka dace don rage jinkirin da suka shafi maganin rigakafi da kuma guje wa rasa mafi kyawun lokacin rigakafin saboda dagewa da jiran rigakafin HPV masu tsada."
A halin yanzu, kamuwa da cutar sankarar mahaifa yana ƙara ƙanana, kuma mata da yawa sun fara kawo 'ya'yansu don tuntuɓar maganin rigakafin HPV.A martanin da ta mayar, Chen Qiuping ya ce, takardar matsayi kan allurar rigakafin cutar ta HPV da Hukumar Lafiya ta Duniya ta fitar, ta jaddada cewa, matakin farko na yawan alurar rigakafin cutar ta HPV, 'yan mata ne masu shekaru 9 zuwa 14, kuma an ba da shawarar allurai biyu na rigakafin cutar ta HPV.Wannan hanyar rigakafin ta fi dacewa da tattalin arziki da dacewa, wanda ke da ma'ana mai girma don haɓaka samun damar rigakafin rigakafi da adadin allurar rigakafi.
Rigakafin cutar sankarar mahaifa bai kamata ya zama “harbi ɗaya” ba, amma ya kamata a riƙa yin gwajin yau da kullun
Bayan rigakafin farko tare da rigakafin HPV, haɗe tare da gwajin cutar kansa na mahaifa na yau da kullun don rigakafin sakandare, yana da mahimmanci don toshe raunukan kansar mahaifa a cikin matakan da suka rigaya da kuma farkon ciwon daji.Ana iya yin gwajin cutar kansa ta mahaifa ta hanyar gwajin HPV na mahaifa da gwajin TCT (gwajin ƙwayar bakin ciki na tushen ruwa).Domin a gano ciwon mahaifa da kuma ciwon mahaifa da wuri-wuri, masana sun ba da shawarar cewa matan da suka wuce shekaru 25 da suka yi jima'i ya kamata a duba su akai-akai.Za su iya zuwa sashin mahaifa, sashen mata ko sashen kula da lafiyar mata na asibiti su tsara tsarin tantancewa bisa shawarar likita.
Tan Xianjie ya ce bai kamata rigakafin cutar kansar mahaifa ya zama "harbi daya ba".Matan da suka kai shekarun da suka dace waɗanda suka yi jima'i su ma suna buƙatar yin gwajin cutar kansar mahaifa bayan sun kammala rigakafin HPV.Gabaɗaya, ana ba da shawarar bincika sau ɗaya kowace shekara biyu kuma daidaita mitar gwargwadon sakamakon gwajin farko.Ganowa da wuri da kuma magance cutar kansar mahaifa na iya taimakawa marasa lafiya su kawar da cutar da wuri-wuri da rage mace-macen cutar kansar mahaifa.Zou Shien ya kuma ba da shawarar cewa babu buƙatar firgita lokacin da aka sami kamuwa da cutar ta HPV ko raunukan mahaifa, kawai ku je wurin likita na yau da kullun.Ko an kamu da HPV ko a'a, ana iya hana kansar mahaifa ta hanyar allurar rigakafi ta HPV tare da tantance cutar kansar mahaifa.
JinDun Medicalyana da haɗin gwiwar bincike na kimiyya na dogon lokaci tare da fasahar kere-kere tare da jami'o'in kasar Sin.Tare da wadataccen albarkatun kiwon lafiya na Jiangsu, tana da dangantakar kasuwanci ta dogon lokaci tare da Indiya, kudu maso gabashin Asiya, Koriya ta Kudu, Japan da sauran kasuwanni.Hakanan yana ba da sabis na kasuwa da tallace-tallace a cikin gabaɗayan tsari daga matsakaici zuwa ƙãre samfurin API.Yi amfani da tarin albarkatun Yangshi Chemical a cikin sinadarai na fluorine don samar da sabis na keɓance sinadarai na musamman ga abokan haɗin gwiwa.Samar da sabbin abubuwa da ayyukan bincike na ƙazanta don ƙaddamar da abokan ciniki.
JinDun Medical ya nace akan ƙirƙirar ƙungiyar tare da mafarkai, yin samfuran tare da mutunci, ƙwarewa, tsauri, da fita gabaɗaya don zama amintaccen abokin tarayya da abokin abokan ciniki!Masu samar da mafita guda ɗaya, R&D na musamman da sabis na samarwa na musamman don matsakaicin magunguna da APIs, sana'amusamman samar da magunguna(CMO) da R&D na Pharmaceutical na musamman da masu samar da sabis (CDMO).
Lokacin aikawa: Mayu-17-2023